The four product patents, two from China and two from Korea are valid through 2025 and 2027, Suven Life Sciences said in a filing to BSE
Drug firm Suven Life Sciences said it has received four product patents in China and Korea for its new chemical entities (NCEs), which could be used for treating various central nervous system disorders.
The four product patents, two from China and two from Korea are valid through 2025 and 2027, Suven Life Sciences said in a filing to BSE.
The company has received approval for molecules that could be used in the treatment of neurodegenerative disorders like Parkinson's, Alzheimer's and Schizophrenia, it added.
Products developed out of these molecules may be out-licensed at various phases of clinical development like Phase I or Phase II, the company said.
Suven CEO Venkat Jasti said the company's pipeline of molecules in CNS arena are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally.
With these new patents, the company has a total of five patents from China and seven patents from Korea, it added.
In the late afternoon, Suven Life Sciences was trading at around Rs14.91 per share on the Bombay Stock Exchange, 9.23% up from the previous close.
With the launch, HCL Infosystems Middle East and Africa (MEA) aims at establishing a foothold to fully implement expansion plans in the region
HCL Infosystems has launched operations in Qatar through a strategic tie up with Dyarco International WLL, a leading business consultancy and subsidiary of Al Faisal Holdings in Qatar.
The company will offer a wide spectrum of ICT products that include computing, storage, networking, security, telecom, imaging and retail.
With the launch, HCL Infosystems Middle East and Africa (MEA) aims at establishing a foothold to fully implement expansion plans in the region.
One of India's top IT hardware, services and ICT system integration firms, the $2.6 billion HCL Infosystems is a one-stop-shop for all ICT requirements.
HCL has specialised expertise across verticals including telecom, BFSI, eGovernance and power.
HCL Infosystems MEA CEO Shivkumar Gopal said the Middle East is an extremely important market for the company, and Qatar is at the very centre of its growth.
"We are very pleased to launch our operations here. In Dyarco, we have found the right partners to establish a strong foothold in this market. By opening our Qatar office, we have now extended our arm in the region with complete resources to manage sales, services and operations locally," he was quoted by Gulf Times as saying.
Headquartered in Doha, Qatar, Dyarco International WLL provides services for establishing various businesses, both domestically and internationally.
"Our presence in Qatar represents a significant step for HCL Infosystems in our transformation strategy to accelerate growth in our targeted international markets offering a complete set of products, service and solutions," said Harsh Chitale, CEO and whole time director, HCL Infosystems Ltd.
"HCL Infosystems is now expanding its global footprint in the Middle East and African market with direct operations in Qatar to address the system integration, services and IT support requirements in these regions," he added.
In the late afternoon, HCL Infosystems was trading at around Rs46.25 per share on the Bombay Stock Exchange, 1.31% up from the previous close.
The approval is for Desogestrel and Ethinyl Estradiol tablets in the strength of 0.15 mg/0.02 mg and for Ethinyl Estradiol tablets in the strength of 0.01 mg
Glenmark Pharmaceuticals said it had received final approval by the US health regulator to market its oral contraceptive Desogestrel and Ethinyl Estradiol tablets in the American market.
Glenmark Generics Inc USA, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (USFDA) for Desogestrel and Ethinyl Estradiol tablets, Glenmark Pharmaceuticals said in a statement.
The company will market their approved product as Viorele TM Tablets and plans to commence shipping immediately, it added.
The approval is for Desogestrel and Ethinyl Estradiol tablets in the strength of 0.15 mg/0.02 mg and for Ethinyl Estradiol tablets in the strength of 0.01 mg.
Viorele TM Tablets are generic version of Teva Women's Health Inc Mircette tablets, Glenmark said.
"According to IMS Health for the 12 month period ending December 2011, the total market sales achieved for Desogestrel & Ethinyl Estradiol tablets USP 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP 0.01 mg were approximately $98 million," it added.
The company's current portfolio consists of 78 generic products authorised for distribution in the US market and 40 ANDA's pending approval with the USFDA.
In the late afternoon, Glenmark Pharmaceuticals was trading at around Rs308 per share on the Bombay Stock Exchange, 1.05% up from the previous close.